

Part I Introduction

1	Introduction: development of skin substitutes	3
	D. P. ORGILL, Brigham and Women's Hospital, USA	
	C. BLANCO, Joseph M. Still Research Foundation, USA	
1.1	Historical development	3
1.2	Skin regeneration	5
1.3	Intellectual property and financial issues	6
1.4	Changing medical practice	7
1.5	References	7
2	Skin replacement products and markets	9
	E. GARFEIN, Montefiore Medical Center, USA	
2.1	Introduction	9
2.2	Indications for skin replacement	10
2.3	The products	12
2.4	The marketplace	15
2.5	Conclusion	16
2.6	References	16
3	Biomechanics of skin	18
	V. SAXENA, Massachusetts Institute of Technology, USA	
3.1	Skin biomechanics	18
3.2	Structure of skin	19
3.3	Definition of mechanical properties	20
3.4	Wounded skin contraction	21
3.5	Modeling skin using finite element methods	22

3.6	Forces on cells	23
3.7	Conclusion	23
3.8	References	23
4	The pathophysiologic basis for wound healing and cutaneous regeneration	25
	D. T. NGUYEN, D. P. ORGILL and G. F. MURPHY, Brigham and Women's Hospital, USA.	
4.1	Introduction	25
4.2	Skin microanatomy and physiology	26
4.3	Wound repair and scar formation	32
4.4	Pathologic wound healing	38
4.5	Comparison between fetal and post-natal skin	39
4.6	Wound repair versus regeneration: fundamental differences	41
4.7	Issues of stem cells and cellular plasticity	45
4.8	Historic developments and future trends	49
4.9	References	51
5	Skin grafts	58
	S. D. IMAHARA and M. B. KLEIN, University of Washington, USA	
5.1	Definitions	58
5.2	Skin anatomy and physiology	58
5.3	Autologous skin grafts	61
5.4	Principles of allogeneic skin grafts	67
5.5	Principles of skin xenografts	72
5.6	Future trends	73
5.7	Summary	74
5.8	References	74
6	Understanding the cellular basis of skin growth	80
	L. GUO, Brigham and Women's Hospital, USA	
6.1	Introduction	80
6.2	Structure of the skin	80
6.3	Skin development and growth	83
6.4	Experimental models for predicting cellular interactions	85
6.5	Conclusions	86
6.6	References	86

7	The regulatory approval process for biomaterials for treating skin loss	87
	J. E. O'GRADY, Integra LifeSciences Corporation, USA	
7.1	Introduction	87
7.2	Regulatory requirements	88
7.3	Medical device approval in the European Union	91
7.4	Combination products	93
7.5	The Global Harmonization Task Force (GHTF)	101
7.6	Quality system	101
7.7	Clinical trials	102
7.8	Humanitarian device exemption	107
7.9	Human tissue and cellular based products	108
7.10	User fees	109
7.11	Future trends in the regulatory process	109
7.12	References	110
Part II	Epidermal and dermal replacement technologies	
8	Alternative delivery of keratinocytes for epidermal replacement	115
	F. M. WOOD, McComb Research Foundation, Burns Service of Western Australia, University of Western Australia, Australia	
8.1	Introduction	115
8.2	Methods of keratinocyte delivery	117
8.3	Direct application	117
8.4	Carrier systems	118
8.5	Summary	119
8.6	References	120
9	Enhancing skin epidermal stability	124
	J. R. SHARPE and N. R. JORDAN, Blond McIndoe Research Foundation, UK; L. J. CURRIE, Derriford Hospital, UK	
9.1	Introduction	124
9.2	Fibrin as a repair material	125
9.3	Hyaluronic acid and Laserskin® as a repair material	129
9.4	Summary	136
9.5	Future trends	137
9.6	References	138

10	Human-derived acellular matrices for dermal replacement	142
	C. T. WAGNER, R. T. OWENS, J. R. HARPER and D. J. MCQUILLAN, LifeCell Corporation, USA	
10.1	Introduction	142
10.2	Processing native tissues	146
10.3	Material characterization	149
10.4	Functional evaluation	159
10.5	Universality of acellular regenerative tissue matrices for soft tissue replacement	164
10.6	Future trends	167
10.7	Sources of further information and advice	168
10.8	References	168
10.9	Disclosure	173
11	Lyophilized xenogenic products for skin replacement	174
	N. MELO and R. SHERIDAN, Massachusetts General Hospital, USA	
11.1	Introduction	174
11.2	Temporary skin substitutes	174
11.3	Permanent skin substitutes	175
11.4	Conclusions	178
11.5	References	178
Part III	Combined dermal and epidermal replacement	
12	Cultured skin substitutes	183
	H. M. POWELL, Shriners Hospitals for Children, USA S. T. BOYCE, Shriners Hospitals for Children and University of Cincinnati, USA	
12.1	Introduction	183
12.2	Medical and surgical objectives for cultured skin substitutes (CSS)	184
12.3	Design and composition of cultured skin substitutes	185
12.4	Clinical considerations	191
12.5	Clinical assessment	193
12.6	Regulatory issues	194
12.7	Future trends	195
12.8	Conclusions	200
12.9	References	200

13	Use of keratinocytes in combination with a dermal replacement to treat skin loss	207
	G. PIETRAMAGGIORI, Brigham and Women's Hospital, USA	
13.1	Simultaneous substitution of dermis and epidermis: from two-step to one-step skin replacement	207
13.2	Cell seeding	208
13.3	Methods of delivery of keratinocytes	208
13.4	References	210
14	Principles of skin regeneration	212
	I. V. YANNAS, Massachusetts Institute of Technology, USA	
14.1	Introduction	212
14.2	The central problem of skin regeneration	213
14.3	Experimental variables in studies of skin regeneration	213
14.4	Applications of the wound closure rule	215
14.5	Scar formation may be secondary to wound contraction	216
14.6	Experimental studies of partial regeneration of skin	217
14.7	Regeneration of adult organs other than skin	219
14.8	Antagonistic relationship between contraction and regeneration	219
14.9	Mechanism of regeneration by use of scaffolds	221
14.10	Future trends	225
14.11	Sources of further information and advice	226
14.12	References	226
15	Summary: biomaterials for treating skin loss	231
	D. P. ORGILL, Brigham and Women's Hospital, USA	
	C. BLANCO, Joseph M. Still Research Foundation, USA	
15.1	Technological advances	231
15.2	Changes in the market for skin substitutes	231
15.3	A more normal skin – regenerative response	233
15.4	References	234
	<i>Index</i>	237